Table 3.
Bivariable analysis for the clinical parameters for the time to recurrence.
| Variable | Number of | Median Months | Rate at | Unadjusted Stratified by Center | Restricted Mean Survival Time | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients (%) | (95% CI) | 3 yr % (95% CI) | 5 yr % (95% CI) | HR (95% CI) | p-Value * | C-Index (95% CI) | Rel. Months (95% CI) | p-Value ** | ||
| Gender | 0.52 (0.46–0.57) | |||||||||
| Male | 87 (79.1) | 61.6 (20–NR) | 58.4 (47.5–71.6) | 51 (38.6–67.5) | 1.0 (reference) | 0.0 (reference) | ||||
| Female | 23 (20.9) | 29.2 (9.4–64.5) | 42.6 (23–78.8) | 28.4 (10.3–77.9) | 1.47 (0.73–2.95) | 0.2845 | −8.9 (−22.2 to 4.5) | 0.1920 | ||
| Previous cancer with chemotherapy or pelvic radiotherapy | 0.5 (0.47–0.54) | |||||||||
| No | 99 (94.3) | 58.3 (20–NR) | 57.2 (47–69.5) | 48 (36.3–63.6) | 1.0 (reference) | 0.0 (reference) | ||||
| Yes | 6 (5.7) | 29.2 (3.4–NR) | 33.3 (7.5–100) | NR (NR–NR) | 1.29 (0.39–4.3) | 0.6774 | −5.3 (−23.8 to 13.1) | 0.5697 | ||
| Professional toxic exposure | 0.54 (0.48–0.6) | |||||||||
| No | 74 (91.4) | 44.9 (14.5–64.5) | 51.9 (40.3–66.9) | 48.7 (36.7–64.6) | 1.0 (reference) | 0.0 (reference) | ||||
| Yes | 7 (8.6) | NR | 85.7 (63.3–100) | 64.3 (33.8–100) | 0.4 (0.09–1.7) | 0.2128 | 22.1 (0.6–43.6) | 0.0435 | ||
| Tobacco use | 0.49 (0.41–0.58) | |||||||||
| No | 27 (27.3) | 29.2 (14.2–NR) | 50 (33.1–75.6) | 43.7 (26.8–71.4) | 1.0 (reference) | 0.0 (reference) | ||||
| Yes | 72 (72.7) | NR | 57.6 (45.6–72.8) | 50.4 (35.5–71.6) | 0.93 (0.48–1.81) | 0.8289 | 6.2 (−10.3 to 22.7) | 0.4642 | ||
| Histologic variant | 0.5 (0.43–0.57) | |||||||||
| UC | 92 (84.4) | 46.5 (20–NR) | 54.6 (43.8–68.1) | 48.9 (37.3–63.9) | 1.0 (reference) | 0.0 (reference) | ||||
| Variant | 17 (15.6) | 58.3 (7.3–NR) | 57.8 (37–90.3) | 38.5 (15.4–96.3) | 1.19 (0.54–2.66) | 0.6656 | 0 (−15.5 to 15.4) | 0.9964 | ||
| T stage | 0.51 (0.48–0.53) | |||||||||
| T2 | 99 (90) | 61.6 (16.4–NR) | 59.3 (48.9–71.8) | 53.6 (42.3–68) | 1.0 (reference) | 0.0 (reference) | ||||
| T3–4 | 7 (6.4) | 20.9 (6.3–NR) | NR (NR–NR) | NR (NR–NR) | 1.93 (0.71–5.27) | 0.1979 | −0.4 (−5.7 to 4.8) | 0.8664 | ||
| N stage | 0.6 (0.46–0.74) | |||||||||
| N0 | 31 (79.5) | NR | 69.3 (52.1–92.1) | 69.3 (52.1–92.1) | 1.0 (reference) | 0.0 (reference) | ||||
| N+ | 8 (20.5) | 11.4 (2.3–29.2) | 15 (2.5–90.6) | NR (NR-NR) | 4.21 (1.1–16.16) | 0.0363 | −17.4 (−30.7 to −4.1) | 0.0103 | ||
| IS biopsy (2 groups) | 0.63 (0.55–0.72) | |||||||||
| ISb-0 | 40 (36.7) | 14.5 (10.4–58.3) | 45.6 (31.4–66.1) | 34.2 (17.4–67.3) | 1.0 (reference) | 0.0 (reference) | ||||
| ISb-1–2 | 69 (63.3) | 61.6 (24.4–NR) | 61.1 (48.6–76.8) | 53.9 (40.5–71.9) | 0.42 (0.23–0.79) | 0.0072 | 14.6 (0.7–28.4) | 0.0391 | ||
| IS biopsy (3 groups) | 0.63 (0.55–0.72) | |||||||||
| ISb-0 | 40 (36.7) | 14.5 (10.4–58.3) | 45.6 (31.4–66.1) | 34.2 (17.4–67.3) | 1.0 (reference) | 0.0 (reference) | ||||
| ISb-1 | 24 (22) | NR | 62.8 (43.2–91.3) | 53.8 (33.3–87.1) | 0.38 (0.16–0.91) | 0.0299 | 16.3 (−1.6 to 34.2) | 0.0751 | ||
| ISb-2 | 45 (41.3) | 61.6 (20–NR) | 59.6 (44.4–80.1) | 53.7 (37.4–77) | 0.44 (0.22–0.88) | 0.0203 | 13.5 (−1.8 to 28.8) | 0.0839 | ||
| Immunoscore (2 groups) | 0.6 (0.53–0.66) | |||||||||
| IS-0–2 | 77 (80.2) | 29.2 (13.7–58.3) | 46.1 (34.3–62.1) | 37 (24–56.9) | 1.0 (reference) | 0.0 (reference) | ||||
| IS-3–4 | 19 (19.8) | NR | 87.2 (71.9–100) | 72.6 (48.4–100) | 0.16 (0.04–0.69) | 0.0135 | 29.7 (11.5–47.9) | 0.0014 | ||
| Immunoscore (3 groups) | 0.65 (0.56–0.75) | |||||||||
| IS-0 | 35 (36.5) | 16.4 (10.4–64.5) | 49.6 (34.3–71.9) | 37.2 (18.9–73.2) | 1.0 (reference) | 0.0 (reference) | ||||
| IS-1–2 | 42 (43.7) | 29.2 (13.7–61.6) | 42.6 (26.7–67.9) | 36.5 (20.9–63.7) | 0.81 (0.41–1.59) | 0.5377 | 0.4 (−15.7 to 16.5) | 0.9610 | ||
| IS-3–4 | 19 (19.8) | NR | 87.2 (71.9–100) | 72.6 (48.4–100) | 0.14 (0.03–0.64) | 0.0107 | 26.4 (8.4–44.3) | 0.0040 | ||
* Wald p Value stratified by participating center. ** Restricted Mean Survival Time p value. IS: Immunoscore; ISb Immunoscore biopsy like.